Top

Published in:

10-08-2023 | Ovarian Cancer | Peritoneal Surface Malignancy

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Authors: Aditi Bhatt, MS, MCh, Olivier Glehen, MD, PhD, Oliver Zivanovic, MD, PhD, Donal Brennan, MB, BCh, PhD, Cedric Nadeau, MD, PhD, Willemien Van Driel, MD, PhD, Naoual Bakrin, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2023

Abstract

Background and Aim

We report the results of an international consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) regimens for epithelial ovarian cancer (EOC) performed with the following goals:

To define the indications for HIPEC
To identify the most suitable HIPEC regimens for each indication in EOC
To identify areas of future research on HIPEC
To provide recommendations for some aspects of perioperative care for HIPEC

Methods

The Delphi technique was used with two rounds of voting. There were three categories of questions: evidence-based recommendations [using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system with the patient, intervention, comparator, and outcome (PICO) method], an opinion survey, and research recommendations.

Results

Seventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41°C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.

Conclusions

The results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.

Available only for authorised users

Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109–19. https://doi.org/10.1159/000521239. (Epub 2022).CrossRefPubMedPubMedCentral

Helderman RFCPA, Löke DR, Tanis PJ, Tuynman JB, Ceelen W, de Hingh IH, van der Speeten K, Franken NAP, Oei AL, Kok HP, Crezee J. Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges. Cancers (Basel). 2021;13(14):3430. https://doi.org/10.3390/cancers13143430.CrossRefPubMedPubMedCentral

Bhatt A, Van Der Speeten K, Hubner M, Kusamura S, Glehen O. ASO Author reflections: standardizing HIPEC methodology and regimens: a prelude to the PSOGI expert consensus. Ann Surg Oncol. 2021;28(13):9114–5. https://doi.org/10.1245/s10434-021-10205-9. (Epub 2021 Jun 4 PMID: 34089108).CrossRefPubMed

Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S, Glehen O. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098–113. https://doi.org/10.1245/s10434-021-10193-w. (Epub 2021 Jun 17 PMID: 34142293).CrossRefPubMed

Kusamura S, Bhatt A, Hubner M, Villeneuve L, Deraco M, Bakrin N, Van Der Speeten K, Glehen O. The PSOGI international consensus on HIPEC regimens for peritoneal malignancies: methodology. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-022-12990-3.CrossRefPubMed

Rowe G, Wright G, Bolger F. Delphi: a re-evaluation of research and theory. Technol Forecast Soc Change. 1991;39:235e51. https://doi.org/10.1016/0040-1625(91)90039-I.CrossRef

Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S. List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. 2021;47(1):4–10. https://doi.org/10.1016/j.ejso.2019.03.012. (Epub 2019 Mar 23 PMID: 30954350).CrossRefPubMed

Guyatt GH, Oxman AD, Akl EA. GRADE guidelines: 1. Introduction e GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383e94. https://doi.org/10.1016/j.jclinepi.2010.04.026.CrossRef

Akinns D, Best D, Briss PA, Eccles M, Falck-Ytter Y. Grades of Recommendation. Assessment, development, and evaluation (GRADE) working group. Education and debate e grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490e4. https://doi.org/10.1136/bmj.328.7454.1490.CrossRef

10.

Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408–14. https://doi.org/10.1002/bjs.5863. (PMID: 17631678).CrossRefPubMed

11.

Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. HIPEC for ovarian cancer collaborators survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–83. https://doi.org/10.1001/jamasurg.2022.0143.CrossRefPubMedPubMedCentral

12.

Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, Chen L, Wang J, Luo J, Jia M, Tang H, He Q, Liao Q, Yang X, Guan T, Wang L, Cui S. Chinese Peritoneal Oncology Study Group. (Gynecologic Oncology Study Group) Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open. 2020;3(8):e2013940. https://doi.org/10.1001/jamanetworkopen.2020.13940.CrossRefPubMedPubMedCentral

13.

van Driel WJ, Koole SN, Sikorska K, van Schagen Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618. (PMID: 29342393).CrossRefPubMed

14.

Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, de Mello CA, Takahashi RM, Nakagawa WT, Aguiar S Jr, Lopes A. Hyperthermic intraperitoneal chemotherapy after primary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis. Ann Surg Oncol. 2016;23(4):1294–301. https://doi.org/10.1245/s10434-015-4991-4. (Epub 2015 Dec 1).CrossRefPubMed

15.

Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol. 2012;127:502–5.PubMed

16.

Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I, Classe JM. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21(11):3621–7. https://doi.org/10.1245/s10434-014-3693-7.CrossRefPubMed

17.

Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–9.PubMed

18.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5. https://doi.org/10.1245/s10434-014-4157-9. (Epub 2014 Nov 13 PMID: 25391263).CrossRefPubMed

19.

Amira G, Morsi A, Fayek IS, Mansour O, Nader H. Hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in recurrent platinum-sensitive ovarian cancer NCI case control study. Asian Pac J Cancer Prev. 2019;20(2):621–7. https://doi.org/10.31557/APJCP.2019.20.2.621. (PMID:30806069 PMCID: PMC6897027).CrossRefPubMedPubMedCentral

20.

Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014;110(6):661–5. https://doi.org/10.1002/jso.23688. (Epub 2014 Jun 24).CrossRefPubMed

21.

Warschkow R, Tarantino I, Lange J, Müller SA, Schmied BM, Zünd M, Steffen T. Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg. 2012;6(1):12. https://doi.org/10.1186/1754-9493-6-12. (PMID: 22709648 PMCID: PMC3407737).CrossRefPubMedPubMedCentral

22.

Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary phase II study. J Clin Oncol. 2021;39(23):2594–604. https://doi.org/10.1200/JCO.21.00605. (Epub 2021 May 21 PMID: 34019431 PMCID: PMC8330970).CrossRefPubMedPubMedCentral

23.

Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21:681–7.PubMed

24.

De Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53–73.PubMed

25.

Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–65.PubMed

26.

Van De Vaart PJ, Van Der Vange N, Zoetmulder FA, Van Goethem AR, Van Tellingen O, Ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148–54.PubMed

27.

Hettinga VE (1996) Reduction of cisplatin resistance by hyperthermia (PhD Thesis, Univ. of Groningen, ISBN 90-367-0648-3) (Printpartners Ipskamp bv, Enschede)

28.

Vos LMC, Aronson SL, van Driel WJ, Huitema ADR, Schagen van Leeuwen JH, Lok CAR, Sonke GS. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:86. https://doi.org/10.1016/j.bpobgyn.2021.06.004. (Epub 2021 Aug 4 PMID: 34565676).CrossRefPubMed

29.

Hetting VE, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin sensitive and -resistant tumor cells. Br J Cancer. 1997;75:1735–43.

30.

Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–42. https://doi.org/10.1016/j.ygyno.2016.05.032. (Epub 2016 Jun 2).CrossRefPubMed

31.

Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase 1 study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136:699–708. https://doi.org/10.1002/ijc.29011.CrossRefPubMed

32.

Los G, Van Vugt MJH, Den Engelse L, Pinedo HM. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharamcol. 1993;46:1229–37.

33.

Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43(2):106–14. https://doi.org/10.1007/s002800050870. (PMID: 9923815).CrossRefPubMed

34.

Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH. Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum. 2020;5(4):20200137. https://doi.org/10.1515/pp-2020-0137.CrossRefPubMedPubMedCentral

35.

Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–14.PubMed

36.

Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009;63:799–805.PubMed

37.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos. 2012;40:2365–73.PubMed

38.

Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol. 2008;15:1407–13.PubMed

39.

Ning S, Macleod K, Abra RM, Huang AH, Hahn GM. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. Int J Radiat Oncol Biol Phys. 1994;29:827–34.PubMed

40.

De Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32:471–82.PubMed

41.

De Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:666–70.PubMed

42.

De Bree E, Rosing H, Filis D, Romanos J, Melissourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15:1183–92.PubMed

43.

Debree E, Katsougkri D, Polioudaki H, Tsangaridou E, Michelakis D, Zoras O, Theodoropoulos P. Hyperthermia during intraperitoneal chemotherapy with paclitaxel or docetaxel for ovarian cancer: is there any benefit? Anticancer Res. 2020;40(12):6769–80. https://doi.org/10.21873/anticanres.14700.CrossRef

44.

Rietbroek RC, Katschinski DM, Reijers MH, Robins HI, Geerdink A, Tutsch K, d’Oleire F, Haveman J. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia. 1997;13(5):525–33. https://doi.org/10.3109/02656739709023551. (PMID: 9354937).CrossRefPubMed

45.

Lee YJ, Lee JY, Cho MS, Nam EJ, Kim SW, Kim S, Kim YT. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. J Gynecol Oncol. 2019;30(1):e3. https://doi.org/10.3802/jgo.2019.30.e3.CrossRefPubMed

46.

Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10(4):463–8. https://doi.org/10.1245/aso.2003.08.006. (PMID: 12734097).CrossRefPubMed

47.

Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101(2):149–55. https://doi.org/10.1002/jso.21448. (PMID: 20035540).CrossRefPubMed

48.

De Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103–10.PubMed

49.

Yonemura Y, Canbay E, Sako S, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Takao N, Ichinose M, Liu Y, Li Y, Ikeda S, Noguchi A, Sai Y. Pharmacokinetics of docetaxel during hyperthermic intraperitoneal chemotherapy for peritoneal metastasis. Gan To Kagaku Ryoho. 2014;41(12):2496–9 (PMID: 25731569).PubMed

50.

Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthemia. 1999;15:79–107.

51.

Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients. Gastroenterol Res Pract. 2012;2012:827534.PubMedPubMedCentral

52.

Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.PubMed

53.

Piché N, Leblond FA, Sidéris L, Pichette V, Drolet P, Fortier LP, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138–44.PubMed

54.

Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, Bereder JM, Quenet F, Meeus P, Marchal F, Morice P, Elias D. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial CHIPOVAC study. Eur J Surg Oncol. 2010;36(6):589–93. https://doi.org/10.1016/j.ejso.2010.04.005.CrossRefPubMed

55.

Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quénet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315–22.PubMed

56.

Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19(7):2352–9. https://doi.org/10.1245/s10434-009-0878-6. (Epub 2009 Dec 29 PMID: 20039210).CrossRefPubMed

57.

Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, Classe JM. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J Surg Oncol. 2011;103(1):10–6. https://doi.org/10.1002/jso.21732. (PMID: 21031424).CrossRefPubMed

58.

Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol. 2009;113(3):335–40. https://doi.org/10.1016/j.ygyno.2009.03.004. (Epub 2009 Apr 5 PMID: 19345401).CrossRefPubMed

59.

Manzanedo I, Pereira F, Serrano Á, Pérez-Viejo E, Martínez-Torres B, Carrión L, Calzas J. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. Clin Transl Oncol. 2019;21(10):1357–63. https://doi.org/10.1007/s12094-019-02065-3. (Epub 2019 Feb 20 PMID: 30788835).CrossRefPubMed

60.

Ansaloni L, Coccolini F, Morosi L, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306–12. https://doi.org/10.1038/bjc.2014.602.CrossRefPubMed

61.

Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052–8. https://doi.org/10.1245/s10434-012-2510-4.CrossRefPubMed

62.

Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2011;2011:185092. https://doi.org/10.1155/2011/185092r.CrossRefPubMedPubMedCentral

63.

Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20. https://doi.org/10.1016/j.ygyno.2011.05.004. (Epub 2011 Jun 12 PMID: 21665254).CrossRefPubMed

64.

Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol. 2011;2011:161862.PubMedPubMedCentral

65.

Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29–44. https://doi.org/10.3978/j.issn.2078-6891.2015.105. (PMID: 26941982; PMCID: PMC4754302).CrossRefPubMedPubMedCentral

66.

Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(480):e1-8.

67.

Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462–8.PubMed

68.

Mercier F, Bakrin N, Bartlett DL, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol. 2018;25:1668–75. https://doi.org/10.1245/s10434-018-6464-z.CrossRefPubMed

69.

Steller M, Egorin M, Trimble E, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106–14. https://doi.org/10.1007/s002800050870.CrossRefPubMed

70.

Kirstein MN, Root SA, Moore MM, Wieman KM, Williams BW, Jacobson PA, Marker PH, Tuttle TM. Exposure-response relationships for oxaliplatin-treated colon cancer cells. Anticancer Drugs. 2008;19(1):37–44. https://doi.org/10.1097/CAD.0b013e3282f07791. (PMID: 18043128).CrossRefPubMed

71.

Cashin PH, Ehrsson H, Wallin I, et al. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol. 2013;69:533–40. https://doi.org/10.1007/s00228-012-1405-4.CrossRefPubMed

72.

Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, Steghens A, Mohamed F, Glehen O. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18(9):2599–603. https://doi.org/10.1245/s10434-011-1651-1. (Epub 2011 Mar 19 PMID: 21424369).CrossRefPubMed

73.

74.

Stewart JH, Shen P, Russell GB, et al. A Phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancer. Ann Surg Oncol. 2008;15:2137–45.PubMedPubMedCentral

75.

Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia: a review. Int J Hyperth. 1997;13:439–57.

76.

Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M. HyNOVA Protocol Steering Committee. Clinical trial protocol for HyNOVA: hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). J Gynecol Oncol. 2022;33(1):e1. https://doi.org/10.3802/jgo.2022.33.e1. (Epub 2021 Oct 18 PMID: 34783204 PMCID: PMC8728663).CrossRefPubMed

77.

Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106(5):1144–53. https://doi.org/10.1002/cncr.21708. (PMID: 16456817).CrossRefPubMed

78.

van Rijswijk RE, Hoekman K, Burger CW, et al. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol. 1997;8(12):1235–41.PubMed

79.

Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314(3):1052–8.PubMed

80.

Elferink F, van der Vijgh WJ, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986;32(4):641–5 (PMID: 3513991).PubMed

81.

Ceresoli M, Coccolini F, Ansaloni L. HIPEC and nephrotoxicity: a cisplatin induced effect? Eur J Surg Oncol. 2016;42(6):909–10. https://doi.org/10.1016/j.ejso.2015.08.174. (Epub 2016 Feb 26 PMID: 26965304).CrossRefPubMed

82.

Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol. 2015;26(1):54–61. https://doi.org/10.3802/jgo.2015.26.1.54. (Epub 2014 Nov 3 PMID: 25376916 PMCID: PMC4302286).CrossRefPubMedPubMedCentral

83.

Markman M, Cleary S, Howell SB. Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate. Am J Clin Oncol. 1986;9(5):440–3. https://doi.org/10.1097/00000421-198610000-00016. (PMID: 3776908).CrossRefPubMed

84.

Guastalla JP, Vermorken JB, Wils JA, et al. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy-a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer. 1994;30(1):45–9.

85.

Patel K, Asare A, Moufarrij S, Costales AB. Sodium thiosulfate for postoperative cisplatin induced nephrotoxicity following hyperthermic intraperitoneal chemotherapy: a case report. Gynecol Oncol Rep. 2021;36:100734. https://doi.org/10.1016/j.gore.2021.100734. (PMID: 33732850; PMCID: PMC7941151).CrossRefPubMedPubMedCentral

86.

Laplace N, Kepenekian V, Friggeri A, Vassal O, Ranchon F, Rioufol C, Gertych W, Villeneuve L, Glehen O, Bakrin N. Sodium thiosulfate protects from renal impairment following hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Int J Hyperthermia. 2020;37(1):897–902. https://doi.org/10.1080/02656736.2020.1795277.CrossRefPubMed

87.

Kurreck A, Gronau F, Alberto Vilchez ME, et al. Sodium thiosulfate reduces acute kidney injury in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with cisplatin: a single-center observational study. Ann Surg Oncol. 2022;29:152–62. https://doi.org/10.1245/s10434-021-10508-x.CrossRefPubMed

88.

Tejedor A, Torres AM, Castilla M, Lazaro JA, de Lucas C, Caramelo C. Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence. Curr Med Res Opin. 2007;23:505–13.PubMed

89.

Markewitz A, Hammer C, Pfeiffer M, Zahn S, Drechsel J, Reichenspurner H, Reichart B. Reduction of cyclosporine induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation. 1994;57:865–70.PubMed

90.

Camaño S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, Lazaro JA, Gomez-Gomez MM, Bosca L, Tejedor A. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther. 2010;334:419–29.PubMed

91.

Humanes B, Lazaro A, Camaño S, Moreno-Gordaliz E, Lazaro JA, Blanco-Codesido M, Lara JM, Ortiz A, Gomez-Gomez MM, Martín-Vasallo P, et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int. 2012;82:652–63.PubMed

92.

Zaballos M, Power M, Canal-Alonso MI, González-Nicolás MÁ, Vasquez-Jimenez W, Lozano-Lominchar P, Cabrerizo-Torrente P, Palencia-García N, Gago-Quiroga S, Ginel-Feito MD, Jiménez C, Lázaro A, González-Bayón L. Effect of cilastatin on cisplatin-induced nephrotoxicity in patients undergoing hyperthermic intraperitoneal chemotherapy. Int J Mol Sci. 2021;22(3):1239. https://doi.org/10.3390/ijms22031239. (PMID: 33513824 PMCID: PMC7865672).CrossRefPubMedPubMedCentral

93.

Vaira M, Barone R, Aghemo B, Mioli PR, De Simone M. Protezione renale con amifostine durante chemioipertermia intraperatoria peritoneale (CIIP) con cisplatino (CDDP) per carcinosi peritoneale. Studio fase I [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study]. Minerva Med. 2001;92(4):207–11 (PMID: 11535965).PubMed

94.

Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43(6):1013–27. https://doi.org/10.1016/j.ejso.2016.09.008. (Epub 2016 Sep 28 PMID: 27727026).CrossRefPubMed

95.

Liutkauskiene S, Grizas S, Jureniene K, et al. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 2018;18:453. https://doi.org/10.1186/s12885-018-4365-y.CrossRefPubMedPubMedCentral

96.

Munker S, Gerken M, Fest P, et al. Chemotherapy for metastatic colon cancer: no effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018;18:455. https://doi.org/10.1186/s12885-018-4380-z.CrossRefPubMedPubMedCentral

97.

Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297–302. https://doi.org/10.1038/sj.bjc.6600139. (PMID: 11953888 PMCID: PMC2375356).CrossRefPubMedPubMedCentral

98.

Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J, Garnier R. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015;53:28–37.PubMed

99.

Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.PubMed

100.

Alzahrani NA, Valle SJ, Fisher OM, et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional experience. J Surg Oncol. 2019;119(3):336–46.PubMed

101.

Batista TP, Dal Molin GZ. Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer? Cancer Drug Resist. 2020;3:666–71. https://doi.org/10.20517/cdr.2020.27.CrossRefPubMedPubMedCentral

102.

Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108:9851–6.PubMedPubMedCentral

103.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res. 2016;76:2868–75.PubMed

104.

Ghirardi V, De Felice F, D’Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference? Cancer Treat Res Commun. 2022;31:100518. https://doi.org/10.1016/j.ctarc.2022.100518. (Epub 2022 Jan 14 PMID: 35065323).CrossRefPubMed

105.

Koole SN, Schouten PC, Hauke J, et al. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. Int J Cancer. 2022;151(8):1394–404. https://doi.org/10.1002/ijc.34124.CrossRefPubMed

106.

Marchetti C, Muzii L, Romito A, Benedetti PP. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;8(12):1095–103. https://doi.org/10.2147/OTT.S155425. (PMID: 30799939 PMCID: PMC6371937).CrossRef

107.

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K 2009 Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every weeks for advanced ovarian cancer a phase 3, open-label, randomised controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(09)61157-0

108.

Feng Z, Wen H, Bi R, Yang W, Wu X. Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecol Oncol. 2016;141(3):466–70. https://doi.org/10.1016/j.ygyno.2016.04.016. (Epub 2016 Apr 23 PMID: 27098361).CrossRefPubMed

109.

Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1 GCIG study. J Clin Oncol. 2017;35(29):3347–53. https://doi.org/10.1200/JCO.2017.73.4293. (Epub 2017 Aug 21 PMID: 28825853).CrossRefPubMed

110.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457–63. https://doi.org/10.1200/JCO.2014.60.5212. (Epub 2015 Jun 29 PMID: 26124480).CrossRefPubMed

111.

Gremonprez F, Willaert W, Ceelen W. Animal models of colorectal peritoneal metastasis. Pleura Peritoneum. 2016;1(1):23–43. https://doi.org/10.1515/pp-2016-0006.CrossRefPubMedPubMedCentral

112.

Moran BJ, Tzivanakis A. The concept of “obstruction-free survival” as an outcome measure in advanced colorectal cancer management. Pleura Peritoneum. 2018;3(1):20180101. https://doi.org/10.1515/pp-2018-0101. (PMID: 30911651 PMCID:PMC6404992).CrossRefPubMedPubMedCentral

113.

Brennan DJ, Driel WJV, Zivanovic O. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer. Int J Gynecol Cancer. 2023;33(5):851–2. https://doi.org/10.1136/ijgc-2023-004411. (PMID: 36898700).CrossRefPubMed

Title: The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer
Authors: Aditi Bhatt, MS, MCh
Olivier Glehen, MD, PhD
Oliver Zivanovic, MD, PhD
Donal Brennan, MB, BCh, PhD
Cedric Nadeau, MD, PhD
Willemien Van Driel, MD, PhD
Naoual Bakrin, MD, PhD
Publication date: 10-08-2023
Publisher: Springer International Publishing
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-13932-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Abstract

Background and Aim

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2023

ASO Visual Abstract: Complications of Thyroid Cancer Surgery in Pediatric Patients at a Tertiary Cancer Center

ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study

Machine-Learning Algorithms Using Systemic Inflammatory Markers to Predict the Oncologic Outcomes of Colorectal Cancer After Surgery

ASO Author Reflections: High-Intensity Focused Ultrasound will Become the Routine Practice for Treatment of Localized Prostate Cancer

Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial

Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer